Dofequidar
Dofequidar (MS-209 free base) is an orally active quinoline compoundthat blocks P-glycoprotein (P-gp) and multidrug resistance-associated protein-1 (MDR-1) . Dofequidar has highly potent reversing effect on multidrug-resistant tumor cells. Dofequidar competitively inhibits ABCB1/P-gp, ABCC1/MRP-1, blocks the efflux of chemotherapeutic agents, increases the drug concentration in cancer cells, and enhances the chemotherapeutic effect[1][2].
Product Specifications
CAS Number
[129716-58-1]
Product Name Alternative
MS-209 (free base)
UNSPSC
12352005
Hazard Statement
H315, H319, H320
Target
P-glycoprotein
Type
Reference compound
Related Pathways
Membrane Transporter/Ion Channel
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/Dofequidar.html
Concentration
10mM
Purity
98.17
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
OC(COC1=C2C=CC=NC2=CC=C1)CN3CCN(C(C(C4=CC=CC=C4)C5=CC=CC=C5)=O)CC3
Molecular Formula
C30H31N3O3
Molecular Weight
481.59
Precautions
H315, H319, H320
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-17013/Dofequidar-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-17013/Dofequidar-SDS-MedChemExpress.pdf
Scientific Category
Reference compound1
Clinical Information
Phase 1
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
CD54 (W-CAM-1; same as Wehi-CAM-1 or 1H4), CF405S conjugate, 0.1mg/mL
